phenyl 4-formyl-2-methoxy-6-methylbenzoate | 1254346-10-5

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 缩酚酸和缩酚酸环醚类
• 英文名称: phenyl 4-formyl-2-methoxy-6-methylbenzoate
• CAS: 1254346-10-5
• 化学式: C₁₆H₁₄O₄
• 分子量: 270.285
• InChiKey: RWMIQGDTZVRJKZ-UHFFFAOYSA-N

物化性质

• 沸点：
  452.4±45.0 °C(Predicted)
• 密度：
  1.202±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.1
• 重原子数：
  20
• 可旋转键数：
  5
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.12
• 拓扑面积：
  52.6
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  phenyl 4-formyl-2-methoxy-6-methylbenzoate 在 甲醇 、 sodium tetrahydroborate 作用下， 反应 0.5h， 生成 Phenyl 4-(hydroxymethyl)-2-methoxy-6-methylbenzoate
  参考文献：
  名称：

  Tetracycline compounds

  摘要：

  本发明涉及一种由结构式（I）表示的化合物，或其药学上可接受的盐。结构式I的变量在此处定义。还描述了包括结构式I化合物的药物组合物及其治疗用途。

  公开号：

  US09315451B2
• 作为产物：
  描述：

  phenyl 4-bromo-2-methoxy-6-methylbenzoate 在 四(三苯基膦)钯 、 potassium carbonate 、 臭氧 作用下， 以 1,4-二氧六环 、 二氯甲烷 、 水 为溶剂， 反应 24.0h， 生成 phenyl 4-formyl-2-methoxy-6-methylbenzoate
  参考文献：
  名称：

  Tetracycline compounds

  摘要：

  本发明涉及一种由结构式（I）表示的化合物，或其药学上可接受的盐。结构式I的变量在此处定义。还描述了包括结构式I化合物的药物组合物及其治疗用途。

  公开号：

  US09315451B2

文献信息

• [EN] TETRACYCLINE ANALOGS<br/>[FR] ANALOGUES DE TÉTRACYCLINE
  申请人：TETRAPHASE PHARMACEUTICALS INC

  公开号：WO2012021712A1

  公开（公告）日：2012-02-16

  The present invention is directed to a compound represented by Structural Formula (I), or a pharmaceutically acceptable salt thereof. The variables for Structural Formula (I) are defined herein. Also described is a pharmaceutical composition comprising the compound of Structural Formula (I) and its therapeutic use.

  本发明涉及一种由结构式(I)表示的化合物，或其药用可接受的盐。结构式(I)的变量在此定义。还描述了一种包括结构式(I)化合物及其治疗用途的药物组合物。
• Tetracycline Compounds
  申请人：Chen Chi-Li

  公开号：US20120135968A1

  公开（公告）日：2012-05-31

  The present invention is directed to a compound represented by Structural Formula (I): or a pharmaceutically acceptable salt thereof. The variables for Structural Formula I are defined herein. Also described is a pharmaceutical composition comprising the compound of Structural Formula I and its therapeutic use.

  本发明涉及一种由结构式(I)表示的化合物或其药学上可接受的盐。结构式I的变量在此定义。同时还描述了包含结构式I化合物的药物组合物及其治疗用途。
• Tetracyline compounds
  申请人：Tetraphase Pharmaceuticals, Inc.

  公开号：US10315992B2

  公开（公告）日：2019-06-11

  The present invention is directed to a compound represented by Structural Formula (I): or a pharmaceutically acceptable salt thereof. The variables for Structural Formula (I) are defined herein. Also described is a pharmaceutical composition comprising the compound of Structural Formula (I), or a pharmaceutically acceptable salt thereof, and its therapeutic use.

  本发明涉及一种由结构式（I）表示的化合物： 或其药学上可接受的盐。结构式（I）的变量在此定义。还描述了一种包含结构式（I）化合物或其药学上可接受的盐的药物组合物及其治疗用途。
• [EN] POLYCYCLIC TETRACYCLINE COMPOUNDS<br/>[FR] COMPOSÉS POLYCYCLIQUES DE TÉTRACYCLINE
  申请人：TETRAPHASE PHARMACEUTICALS INC

  公开号：WO2011123536A8

  公开（公告）日：2012-02-02
• Synthesis and Biological Evaluation of 8-Aminomethyltetracycline Derivatives as Novel Antibacterial Agents
  作者：Roger B. Clark、Minsheng He、Yonghong Deng、Cuixiang Sun、Chi-Li Chen、Diana K. Hunt、William J. O’Brien、Corey Fyfe、Trudy H. Grossman、Joyce A. Sutcliffe、Catherine Achorn、Philip C. Hogan、Christopher E. Katz、John Niu、Wu-Yan Zhang、Zhijian Zhu、Magnus Ronn、Xiao-Yi Xiao

  DOI：10.1021/jm401211t

  日期：2013.10.24

  The C-8 position of the tetracyclines has been largely underexplored because of limitations in traditional semisynthetic techniques. Employing a total synthetic approach allowed for modifications at the C-7 and C-8 positions, enabling the generation of structure activity relationships for overcoming the two most common tetracycline bacterial-resistance mechanisms: ribosomal protection (tet(M)) and efflux (tet(A)). Ultimately, several compounds were identified with balanced activity against both Gram-positive and Gram-negative bacteria, including pathogens bearing both types of tetracycline-resistance mechanisms. Compounds were screened in a murine systemic infection model to rapidly identify compounds with oral bioavailability, leading to the discovery of several compounds that exhibited efficacy when administered orally in murine pyelonephritis and pneumonia models.